Exelixis inc (NASDAQ:EXEL) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Exelixis inc (NASDAQ:EXEL) gained 1.43 Percent and closed its previous trading session at $21.92. The stock traded with the average Volume of 4.48 Million at the end of last session.
Exelixis inc (NASDAQ:EXEL) has the Market Capitalization of 6.57 Billion. The Stock has its 52-week High of $32.50 and 52-Week Low of $18.50 and it touched its 52-week high on 10/16/17 and 52-Week Low on 05/10/18
The company reported its last earnings Actual EPS of $0.37/share. While, the analyst predicted that the company could provide an EPS of $0.16/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.21/share which shows an Earnings Surprise of 131.2 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Exelixis inc (NASDAQ:EXEL) as Buy, 1 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 6.29% where SMA50 and SMA200 are 6.24% and -11.51% respectively.
The company shows its Return on Assets (ROA) value of 39.6%. The Return on Equity (ROE) value stands at 75.5%. While it’s Return on Investment (ROI) value is 55.4%.
Exelixis inc (NASDAQ:EXEL) currently has a Weekly Volatility of 3.25% percent while its Monthly Volatility is at 3.45% percent. While talking about Performance of the Stock, Exelixis inc currently has a Weekly performance of 3.54%, monthly performance percentage is 13.69 percent, Quarterly performance is 5.13 percent, 6 months performance shows a percent value of -26.91% and Yearly Performance is -17.62 percent.
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ(r) (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.